Caladrius CEO Predicts Tenfold Market Cap Rise As Pipeline ‘Validates’ Itself
Executive Summary
The CEO of US-based Caladrius Biosciences believes its share price will rise at least tenfold over the next three years as the cell therapy specialist’s pipeline advances to commercialization.